Details of the Drug Combination

General Information of Drug Combination (ID: DC7XZZ6)

Drug Combination Name
Zanamivir Zanamivir
Indication
Disease Entry Status REF
Influenza A Virus, H1N1 Subtype Phase 1 [1]
Component Drugs Zanamivir   DMFMBZ4 Zanamivir   DMFMBZ4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Zanamivir
Disease Entry ICD 11 Status REF
Influenza 1E30-1E32 Approved [2]
Influenza virus infection 1E30-1E32 Approved [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [4]
Zanamivir Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Influenza Neuraminidase (Influ NA) TT50QJ3 NRAM_I33A0 Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Zanamivir
Disease Entry ICD 11 Status REF
Influenza 1E30-1E32 Approved [2]
Influenza virus infection 1E30-1E32 Approved [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [4]
Zanamivir Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Influenza Neuraminidase (Influ NA) TT50QJ3 NRAM_I33A0 Inhibitor [5]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00989404) Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
2 Zanamivir FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 021036
4 Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004 Apr;10(4):581-6. doi: 10.3201/eid1004.030458.
5 Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.